Developments in early recall memory: normative trends and individual differences.

P. Bauer,M. Burch,E. Kleinknecht

DOI: https://doi.org/10.1016/S0065-2407(02)80040-4

Advances in child development and behavior

Abstract:

What problem does this paper attempt to address?

Antigen-specific Killer Polylactic-Co-glycolic Acid Microspheres Selectively Deplete Antigen-Specific T Cells in Vitro and in Vivo (TRAN1P.924)

Wei Wang,Miaochen Li,Kun Fang,You Wu,Ning Gu,Chuanlai Shen

DOI: https://doi.org/10.4049/jimmunol.194.supp.140.6

2015-01-01

Abstract:Abstract The strategy of specifically depleting antigen-specific T cells can potentially be used to treat allograft rejection and autoimmunity because it does not suppress the overall immune systems. In this study, we generated killer polylactic-co-glycolic acid (PLGA) microspheres by covalently coupling H-2Kb-Ig and apoptosis-inducing anti-Fas monoclonal antibody (mAb) onto cell-sized PLGA microspheres. The Kb/OVA257-264-Killer PLGAs resulted in a dramatic reduction in the number of OVA257-264-specific CD8+ T cells in an antigen-specific manner in vitro and in vivo, by using a transgenic OT-1 mice model. The bioluminescence imaging revealed that Killer PLGAs dominantly distributed in lung, liver and gut, and was maintained for up to 48 hours in OT-1 mice and a longer time in OT-1 mice than in C57BL/6 mice. Moreover, the Kb-Killer PLGAs were administered intravenously into bm1 mice (H-2Kbm1) that had previously been grafted with ear skin from C57BL/6 mice (H-2Kb). The killer PLGAs selectively decreased the H-2Kb alloantigen-reactive CD8+ T cells infiltrating into the alloskin graft but not CD4+ T cells, and significantly prolonged allograft survival for 41.5 days without the impairment of host overall immune function. Thus, our data highlight the therapeutic potential of this biocompatible and biodegradable killer effectors for the treatment of allograft rejection and autoimmune disease. Keywords: Allograft rejection, PLGA, H-2Kb-Ig
Introduction to a Special Issue: Childbirth History is Everyone’s History

E. Declercq

DOI: https://doi.org/10.1093/jhmas/jrx057

2018-01-05

Journal of the History of Medicine and Allied Sciences

Abstract:More than any other endeavor, save death, the history of childbirth is quite literally everyone’s history. The stories recounted in this volume remind us of the broad themes that have dominated the history of childbirth in the United States for the last century and continue to resonate today. These include debates over the place of birth, the benefits and limitations of medical intervention and technology in birth, the status of women as providers of care and decision makers concerning their own maternity care. How are these themes manifested in contemporary US maternity care? After a steady rise from 1996-2009 that resulted in the highest cesarean rate in US history (32.9%), the cesarean rate has been decreasing at a glacial pace to a 2016 rate of 31.9%. The current rate is still far beyond what evidence suggests it should be, if this abdominal surgery was only about improving health outcomes, but what was seen as an inevitable increase in cesareans has not occurred. Rates of other interventions, such as medical induction of labor, electronic fetal monitoring and epidural anesthesia are also at all-time highs, though these too have largely plateaued. Nonetheless, the ongoing tension between medical intervention and a desire for a more humanized approach to birth continues to resonate in contemporary practice. There has also been a resurgence of public interest in the health of mothers in childbirth, ranging from questioning their pre-pregnancy health, particularly related to
Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.

Wei Wang,Kun Fang,Xiaobing Wang,Miaochen Li,You Wu,Feng Chen,Khawar Ali Shahzad,Ning Gu,Chuanlai Shen

DOI: https://doi.org/10.3109/08820139.2015.1014098

2015-01-01

Immunological Investigations

Abstract:Background: The strategy of specifically depleting antigen-specific T cells can potentially be used for the treatment of allograft rejection and autoimmunity because it does not suppress the overall immune systems. Methods: In this study, we generated killer polylactic-co-glycolic acid (PLG-A) microspheres by covalently coupling major histocompatibility complex (AMC) class I antigens and apoptosis-inducing anti-Fas monoclonal antibody (mAb) onto PLGA microspheres. A modified double-emulsion method was used for the preparation of cell-sized PLGA microspheres. H-2K(b)/peptide monomers were generated in-house and analyzed through flow cytometry. The killer PLGA microspheres were administered intravenously into BALB/c mice (H-2K(b)) that had previously been grafted with skin squares from C57BL/6 mice (H-2K(b)). Tumor cell challenge and third-party mixed lymphocyte culture were used to assess the general immune functions of host. Results: The alloskin graft survival was prolonged by 4 days. The killer PLGA microspheres could specifically deplete the H-2K(b) alloantigen-reactive CD8 T cells that infiltrated into the alloskin graft but not CD4(+) T cells, without impairment of host overall immune function. Conclusions: Here, we initially report that PLGA microspheres, which have been,videly used as medicine-delivering carriers, were used to prepare antigen-specific killer complexes and treat allograft rejection. Our data highlight the therapeutic potential of this biocompatible and biodegradable antigen-specific killer effector for the treatment of allograft rejection and autoimmune disease.
Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

Baohong Luo,Yikang Zhan,Minqi Luo,Huimin Dong,Jun Liu,Yingtong Lin,Junsong Zhang,Guanwen Wang,Els Verhoeyen,Yiwen Zhang,Hui Zhang

DOI: https://doi.org/10.1038/s41419-020-03187-1

2020-01-01

Cell Death and Disease

Abstract:Long-lived plasma cells (LLPCs) are robust specialized antibody-secreting cells that mainly stay in the bone marrow and can persist a lifetime. As they can be generated by inducing the differentiation of B-lymphocytes, we investigated the possibility that human LLPCs might be engineered to express α-PD-1 monoclonal antibody to substitute recombinant α-PD-1 antitumor immunotherapy. To this end, we inserted an α-PD-1 cassette into the GAPDH locus through Cas9/sgRNA-guided specific integration in B-lymphocytes, which was mediated by an integrase-defective lentiviral vector. The edited B cells were capable of differentiating into LLPCs both in vitro and in vivo. Transcriptional profiling analysis confirmed that these cells were typical LLPCs. Importantly, these cells secreted de novo antibodies persistently, which were able to inhibit human melanoma growth via an antibody-mediated checkpoint blockade in xenograft-tumor mice. Our work suggests that the engineered LLPCs may be utilized as a vehicle to constantly produce special antibodies for long-term cellular immunotherapy to eradicate tumors and cellular reservoirs for various pathogens including human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV).
Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Yingying Shi,Zeliang Lou,Yu Liu,Jiaxin Huang,Yi Wang,Jian You

DOI: https://doi.org/10.1002/adfm.202304823

IF: 19

2023-09-17

Advanced Functional Materials

Abstract:In this work, core–shell structured nanoparticles co‐loaded with allogeneic antigen (Ag) and immunosuppressive agent Tacrolimus (Ag@FK506‐NPs) are constructed for sequential drug release and Ag epitope‐specific recognition and deletion of recipient alloreactive T cells, which yields good antirejection effect without compromising the overall immunity in a murine fully major histocompatibility complex‐mismatched skin allograft model. Allogeneic grafts are vulnerable to the attack launched by host alloreactive T cells, which accounts primarily for allograft failure in the clinic. Conventional pharmacological intervention mainly involves broad‐acting, nonspecific immunosuppressants that provide limited protection over the graft and may cause deleterious side effects due to insufficient allospecificity. Here, core–shell structured nanoparticles co‐loaded with allogeneic antigen (Ag) and immunosuppressive agent Tacrolimus (Ag@FK506‐NPs) are constructed. Dendritic cells (DCs) pulsed with Ag@FK506‐NPs present alloantigenic epitopes on the cell surface as a bait to capture specific T cells, especially CD8+ T cells, for intercellular FK506 transfer and alloreactive T‐cell deletion. Meanwhile, DCs are maintained in an immature tolerogenic state that induces the functional inactivation of recruited T cells. Compared with free FK506, the adoptive transfer of low immunosuppressant dose (25 000‐fold lower) of Ag@FK506‐NPs pulsed DCs is enough to yield a superior antirejection effect in a major histocompatibility complex‐mismatched murine skin transplant model. Of note, due to the cell–cell communication conferred selective T‐cell suppression, the recipient mouse is able to respond to the subsequent stimulation of an irrelevant Ag, indicating that off‐target toxicity is bypassed. Overall, this work may address some of the limitations of current allograft therapeutics.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Jia Shen,Chang Liu,Pengpeng Yan,Meifang Wang,Luying Guo,Shuaihui Liu,Jianghua Chen,Jessica M. Rosenholm,Hongfeng Huang,Rending Wang,Hongbo Zhang

DOI: https://doi.org/10.34133/2022/9794235

2022-01-01

Abstract:Antibody-mediated rejection (ABMR) is a major cause of dysfunction and loss of transplanted kidney. The current treatments for ABMR involve nonspecific inhibition and clearance of T/B cells or plasma cells. However, the prognosis of patients following current treatment is poor. T follicular helper cells (Tfh) play an important role in allograft-specific antibodies secreting plasma cell (PC) development. Tfh cells are therefore considered to be important therapeutic targets for the treatment of antibody hypersecretion disorders, such as transplant rejection and autoimmune diseases. Tacrolimus (Tac), the primary immunosuppressant, prevents rejection by reducing T cell activation. However, its administration should be closely monitored to avoid serious side effects. In this study, we investigated whether Tac delivery to helper T (CD4 + ) cells using functionalized mesoporous nanoparticles can block Tfh cell differentiation after alloantigen exposure. Results showed that Tac delivery ameliorated humoral rejection injury in rodent kidney graft by suppressing Tfh cell development, PC, and donor-specific antibody (DSA) generation without causing severe side effects compared with delivery through the drug administration pathway. This study provides a promising therapeutic strategy for preventing humoral rejection in solid organ transplantation. The specific and controllable drug delivery avoids multiple disorder risks and side effects observed in currently used clinical approaches.
Killer artificial antigen-presenting cells treating skin allograft rejection and its impact on the overall immune function in mice model

Miao-chen LI,Wei WANG,Xiao-e LI,Kun FANG,You WU,Ning GU,Chuan-Iai SHEN

DOI: https://doi.org/10.3969/j.issn.1671-6264.2015.04.002

2015-01-01

Abstract:Objective: To study the therapeutic effect for skin allograft rejection of killer artificial antigen-presenting cells( KaAPC) and its impact on the overall immune function in mice model.Methods: KaAPC were prepared by co-coupling H-2Kb antigen and anti-Fas monoclonal antibody onto the biodegradable polylactic-co-glycolic acid ( PLGA) microspheres, and then were administered intravenously into BALB/c mice ( H-2Kd ) that had previously been grafted with skin squares from C57BL/6 mice (H-2Kb).Tumor cell challenge and third-party mixed lymphocyte culture were used to assess the general immune functions of host.Results:KaAPC microspheres had the correct phenotype as verified by FACS;the skinallograft survival was prolonged significantly(P<0.000 1) after treatment with KaAPC;the proliferation of recipient T cells against the third-party splenocytes and the defense to tumor did not apparently decreased after treatment with KaAPC in therapy mice.Conclusion:The KaAPC have ability to inhibit skin allograft rejection in mice model, without impairment of host overall immune function.
Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy

B Wu,J M Wu,A Miagkov,R N Adams,H I Levitsky,D B Drachman

DOI: https://doi.org/10.4049/jimmunol.166.7.4773

2001-04-01

Abstract:We tested the hypothesis that APCs genetically engineered to present an Ag and to express Fas ligand (FasL) simultaneously can target and eliminate Ag-specific T cells. Transgenic T cells specific for influenza hemagglutinin (HA) were used as targets. We prepared recombinant vaccinia virus vectors (VVV) to transfer the gene constructs individually or simultaneously into APCs. We prevented unwanted viral replication by attenuating the VVVs with psoralen-UV light treatment. For presentation of the HA Ag, APCs were transduced with cDNA for HA flanked by sequences of the lysosome-associated membrane protein that direct efficient processing and presentation of the Ag by APCs. As a "warhead" for the APCs, we transduced them with the gene for FasL, which induces apoptosis of Fas-expressing activated T cells. To protect the transduced APCs from self-destruction by FasL, we transferred cDNA for a truncated form of Fas-associated death domain, which inhibits Fas-mediated cell death. Our results show that the engineered APCs effectively expressed the genes of interest. APCs transduced with VVV carrying all three gene constructs specifically killed HA-transgenic T cells in culture. Coculture with T cells specific for an unrelated Ag (OVA) had no significant effect. Our in vitro findings show that APCs can be genetically engineered to target and kill Ag-specific T cells and represent a promising novel strategy for the specific treatment of autoimmune diseases.
Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury.

Jinwen Lin,Junhao Lv,Xianping Yu,Xing Xue,Shiping Yu,Huiping Wang,Jianghua Chen

DOI: https://doi.org/10.1021/acsami.3c06885

IF: 9.5

2023-01-01

ACS Applied Materials & Interfaces

Abstract:Disturbance of single-cell transcriptional heterogeneity is an inevitable consequence of persistent donor-specific antibody (DSA) production and allosensitization. However, identifying and efficiently clearing allospecific antibody repertoires to restore single-cell transcriptional profiles remain challenging. Here, inspired by the high affinity of natural bacterial proteins for antibodies, a genetic engineered membrane-coated nanoparticle termed as DSA trapper by the engineering chimeric gene of protein A/G with phosphatidylserine ligands for macrophage phagocytosis was reported. It has been shown that DSA trappers adsorbed alloreactive antibodies with high saturation and activated the heterophagic clearance of antibody complexes, alleviating IgG deposition and complement activation. Remarkably, DSA trappers increased the endothelial protective lineages by 8.39-fold, reversed the highly biased cytotoxicity, and promoted the proliferative profiles of Treg cells, directly providing an obligate immune tolerant niche for single-cell heterogeneity restoration. In the mice of allogeneic transplantation, the DSA trapper spared endothelial from inflammatory degenerative rosette, improved the glomerular filtration rate, and prolonged the survival of allogeneic mice from 23.6 to 78.3 days. In general, by identifying the lineage characteristics of rejection-related antibodies, the chimeric engineered DSA trapper realized immunoadsorption and further phagocytosis of alloantibody complexes to restore the single-cell genetic architecture of the allograft, offering a promising prospect for the treatment of alloantibody-mediated immune injury.
Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Jiong Tian,Oliver Pabst,Dorothee Roemermann,Susanne Skubich,Reinhold Foerster,Jan Beckmann,Jiang-Hua Chen,Matthias W. Hoffmann

DOI: https://doi.org/10.1097/01.tp.0000269724.06142.92

2007-01-01

Transplantation

Abstract:Background. Signaling through the T cell receptor (TCR) leads to profound changes in the function and properties of T cells, including integrin activation. Adhesion and degranulation promoting adapter protein (ADAP) is an adapter protein linking T cell receptor stimulation to integrin activation. We aim to clarify how disruption of TCR-mediated integrin activation affects alloreactive immune responses.Methods. In vitro T cell proliferation and the cytokine production was determined. In vivo cytotoxic T lymphocyte (CTL) activity was measured as well. Allogenic skin and heart transplantation was used to test the in vivo role of ADAP in alloimmune responses. Histology and flow cytometry was applied to analyze the graft infiltrating lymphocytes.Results. Upon stimulation with allogenic dendritic cells ADAP-deficient T cells displayed impaired proliferative responses compared to wild type (WT) T cells. This was accompanied by significantly decreased production of the cytokine interleukin-2. In contrast, the in vivo CTL activity in ADAP-deficient mice was comparable to that of WT mice. Consistently, we observed a prolongation of fully major histocompatibility complex (MHC)-mismatched heart transplants in ADAP deficient mice. Protection of allogenic heart grafts in ADAP-deficient mice was accompanied by a decrease in the infiltration, proliferation and activation of T cells in the allograft. However, no effect was observed after fully MHC-mismatched skin transplantation.Conclusions. We have shown that although ADAP is dispensable for the rejection of allografts, ADAP function plays an important role for the efficacy of graft rejection. ADAP's main function appears to affect the induction phase of the immune response.
Antigen-specific T cell immunotherapy by in vivo mRNA delivery

Fang-Yi Su,Jamison C. Siebart,Ching S. Chan,Matthew Y. Wang,Xinyi Yao,Aaron D. Silva Trenkle,Avanti Sivakumar,Melanie Su,Rustin Harandi,Neha Shahrawat,Chi H. Nguyen,Anshika Goenka,Jinhee Mun,Madhav V. Dhodapkar,Gabriel A. Kwong

DOI: https://doi.org/10.1101/2024.10.29.620946

2024-11-03

Abstract:Immunotherapy has shown promise for treating patients with autoimmune diseases or cancer, yet treatment is associated with adverse effects associated with global activation or suppression of T cell immunity. Here, we developed antigen-presenting nanoparticles (APNs) to selectively engineer disease antigen (Ag)-specific T cells by in vivo mRNA delivery. APNs consist of a lipid nanoparticle core functionalized with peptide-major histocompatibility complexes (pMHCs), facilitating antigen-specific T cell transfection through cognate T cell receptor-mediated endocytosis. In mouse models of type 1 diabetes and multiple myeloma, APNs selectively deplete autoreactive T cells leading to durable control of glycemia, and engineer virus-specific T cells with anti-cancer chimeric antigen receptors (CARs), achieving comparable therapeutic outcome as virally transduced ex vivo CAR. Overall, our work supports the use of APNs to engineer disease-relevant T cells in vivo as Ag-specific immunotherapy for autoimmune disorders and cancer.

Bioengineering
In Situ Genetic Engineering of Host T-cells Based on Acellular Scaffold Strategy: a Big but Also Small Step for Solid Tumor Immunotherapy

Shu-Yan Han,Zi-Xuan Zhao,Jun Wu

DOI: https://doi.org/10.1186/s40779-024-00517-8

2024-01-01

Military Medical Research

Abstract:Background Targeted T-cell therapy has emerged as a promising strategy for the treatment of hematological malignancies. However, its application to solid tumors presents significant challenges due to the limited accessibility and heterogeneity. Localized delivery of tumor-specific T-cells using biomaterials has shown promise, however, procedures required for genetic modification and generation of a sufficient number of tumor-specific T-cells ex vivo remain major obstacles due to cost and time constraints. Methods Polyethylene glycol (PEG)-based three-dimensional (3D) scaffolds were developed and conjugated with positively charged poly-L-lysine (PLL) using carbamide chemistry for efficient loading of lentiviruses (LVs) carrying tumor antigen-specific T-cell receptors (TCRs). The physical and biological properties of the scaffold were extensively characterized. Further, the scaffold loaded with OVA-TCR LVs was implanted in B16F10 cells expressing ovalbumin (B16-OVA) tumor model to evaluate the anti-tumor response and the presence of transduced T-cells. Results Our findings demonstrate that the scaffolds do not induce any systemic inflammation upon subcutaneous implantation and effectively recruit T-cells to the site. In B16-OVA melanoma tumor-bearing mice, the scaffolds efficiently transduce host T-cells with OVA-specific TCRs. These genetically modified T-cells exhibit homing capability towards the tumor and secondary lymphoid organs, resulting in a significant reduction of tumor size and systemic increase in anti-tumor cytokines. Immune cell profiling revealed a significantly high percentage of transduced T-cells and a notable reduction in suppressor immune cells within the tumors of mice implanted with these scaffolds. Conclusion Our scaffold-based T-cell therapy presents an innovative in situ localized approach for programming T-cells to target solid tumors. This approach offers a viable alternative to in vitro manipulation of T-cells, circumventing the need for large-scale in vitro generation and culture of tumor-specific T-cells. It offers an off-the-shelf alternative that facilitates the use of host cells instead of allogeneic cells, thereby, overcoming a major hurdle.
De novo designed pMHC binders facilitate T cell induced killing of cancer cells

Kristoffer Haurum Johansen,Darian Wolff,Beatrice Scapolo,Monica L. Fernandez-Quintero,Charlotte Risager Christensen,Johannes R. Loeffler,Esperanza Rivera-de-Torre,Max D. Overath,Kamilla Kjaergaard Munk,Oliver Morell,Marie Christine Viuff,Alberte T. Damm Englund,Mathilde Due,Stefano Forli,Emma Qingjie Andersen,Jordan Sylvester Fernandes,Suthimon Thumtecho,Andrew B. Ward,Maria Ormhoj,Sine Reker Hadrup,Timothy P. Jenkins

DOI: https://doi.org/10.1101/2024.11.27.624796

2024-12-03

Abstract:The recognition of intracellular antigens by CD8+ T cells through T cell receptors (TCRs) is central to adaptive immunity, enabling responses against infections and cancer. The recent approval of TCR-gene-edited T cells for cancer therapy demonstrates the therapeutic advantage of using pMHC recognition to eliminate cancer. However, identification and selection of TCRs from patient material is complex and influenced by the TCR repertoire of the donors used. To overcome these limitations, we here present a rapid and robust de novo binder design platform leveraging state-of-the-art generative models, including RFdiffusion, ProteinMPNN, and AlphaFold2, to engineer minibinders (miBds) targeting the cancer-associated pMHC complex, NY-ESO-1(157-165)/HLA-A*02:01. By incorporating in silico cross-panning and molecular dynamics simulations, we enhanced specificity screening to minimise off-target interactions. We identified a miBd that exhibited high specificity for the NY-ESO-1-derived peptide SLLMWITQC in complex with HLA-A*02:01 and minimal cross-reactivity in mammalian display assays. We further demonstrate the therapeutic potential of this miBd by integrating it into a chimeric antigen receptor, as de novo Binders for Immune-mediated Killing Engagers (BIKEs). BIKE-transduced T cells selectively and effectively killed NY-ESO-1+ melanoma cells compared to non-transduced controls, demonstrating the promise of this approach in precision cancer immunotherapy. Our findings underscore the transformative potential of generative protein design for accelerating the discovery of high-specificity pMHC-targeting therapeutics. Beyond CAR-T applications, our workflow establishes a foundation for developing miBds as versatile tools, heralding a new era of precision immunotherapy.

Immunology
Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

David A. Horwitz,Ju Hua Wang,Dongin Kim,Chang Kang,Katja Brion,Sean Bickerton,Antonio La Cava

DOI: https://doi.org/10.3389/fimmu.2024.1429335

IF: 7.3

2024-07-26

Frontiers in Immunology

Abstract:We have previously reported that nanoparticles (NPs) loaded with IL-2 and TGF-β and targeted to T cells induced polyclonal T regulatory cells (Tregs) that protected mice from graft-versus-host disease (GvHD). Here, we evaluated whether administration of these NPs during alloantigen immunization could prevent allograft rejection by converting immunogenic responses to tolerogenic ones. Using C57BL/6 mice and BALB/c mice as either donors or recipients of allogeneic splenocytes, we found that treatment with the tolerogenic NPs in both strains of mice resulted in a marked inhibition of mixed lymphocyte reaction (MLR) to donor cell alloantigen but not to third-party control mouse cells after transfer of the allogeneic cells. The decreased alloreactivity associated with a four- to fivefold increase in the number of CD4 + and CD8 + T regulatory cells (Tregs) and the acquisition of a tolerogenic phenotype by recipient dendritic cells (DCs) in NP-treated mice. As allogeneic cells persisted in NP-treated mice, these findings suggest that tolerogenic NPs can induce alloantigen-specific Tregs and tolerogenic DCs promoting tolerogenic responses to alloantigen. By inhibiting reactivity to allotransplant, this approach could help reduce the need for immune suppression for the maintenance of allografts.

immunology
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy

Xiaoqiong Zhang,Zhaohan Wei,Tuying Yong,Shiyu Li,Nana Bie,Jianye Li,Xin Li,Haojie Liu,Hang Xu,Yuchen Yan,Bixiang Zhang,Xiaoping Chen,Xiangliang Yang,Lu Gan

DOI: https://doi.org/10.1038/s41467-023-41438-9

IF: 17.694

2023-09-14

NanoScience and Technology

Abstract:The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8 + T cells, especially stem-like CD8 + T cells, in tumor tissues. Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R848@M2pep-MPs AFP ) for enhanced anti-PD-1 therapy in HCC. R848@M2pep-MPs AFP target and reprogram immunosuppressive M2-like tumor-associated macrophages (TAMs) into M1-like phenotype. Meanwhile, R848@M2pep-MPs AFP -reprogrammed TAMs act as antigen-presenting cells, not only presenting AFP antigen to activate CD8 + T cell-mediated antitumor immunity, but also providing an intra-tumoral niche to maintain and differentiate stem-like CD8 + T cells. Combination immunotherapy with anti-PD-1 antibody generates strong antitumor immune memory and induces abundant stem-like CD8 + T cell proliferation and differentiation to terminally exhausted CD8 + T cells for long-term immune surveillance in orthotopic and autochthonous HCC preclinical models in male mice. We also show that the R848-loaded engineered MPs derived from macrophages overexpressing a model antigen ovalbumin (OVA) can improve anti-PD-1 therapy in melanoma B16-OVA tumor-bearing mice. Our work presents a facile and generic strategy for personalized cancer immunotherapy to boost anti-PD-1 therapy.
Efficient And Selective Prevention Of Graft-Versus-Host Disease By Ag-Specific Induced Regulatory T Cells In Mice

Kenrick Semple,Yu Yu,Dapeng Wang,Claudio Anasetti,Xue-Zhong Yu

DOI: https://doi.org/10.1182/blood.v116.21.3745.3745

IF: 20.3

2010-01-01

Blood

Abstract:Abstract Abstract 3745 Naturally occurring regulatory T cells (nTregs) suppress the development of graft-versus-host disease (GVHD). The non-selective suppression against tumor associated antigens in some models severely dampened our enthusiasm for the application of nTregs in the control of GVHD after allogeneic hematopoietic cell transplantation (HCT). In this study, we used an alternative strategy to generate antigen-specific, induced Tregs (iTregs), and tested their potential in the prevention of GVHD in murine model of myeloablative BMT. CD4+CD25+Foxp3+ iTregs generated from OT-II TCR transgenic mice specific for OVA target antigen efficiently prevented GVHD induced by polyclonal T effector cells (Teffs) in allogeneic recipients that express OVA protein but not in those that do not express OVA. The efficacy of these antigen-specific iTregs was significantly higher than polyclonal iTregs in preventing GVHD. As controls, OT-II CD4+Foxp3− cells had no effect on GVHD development in OVA− recipients and exacerbated GVHD in OVA+ recipients when transplanted together with polyclonal Teffs. Mechanistically, OT-II iTregs expanded extensively, and significantly suppressed expansion and infiltration of Teffs in OVA+ recipients. In sharp contrast, OT-II iTregs failed to expand and had no effect on Teffs in OVA− recipients. These results reveal the therapeutic potential of TGFβ-induced, antigen-specific iTregs to prevent GVHD efficiently and selectively. Disclosures: No relevant conflicts of interest to declare.
In Vivo Anti-Melanoma Eycacy of Allo-Restricted CTLs Speciwc for Melanoma Expanded by Artiwcial Antigen-Presenting Cells

Xiaoling Lü,Xiaobing Jiang,Ru-en Liu,Shengmin Zhang

2009-01-01

Abstract:Cytotoxic CD8 + T cells are key eVectors in the immunotherapy of malignant and viral diseases. However, autologous T cell responses to tumor antigens presented by self-MHC are usually weak and ineVective. Allo-restricted T cells represent a potent source of tumor-speciWc T cells for adoptive immunotherapy. This study reports in vivo anti-melanoma eYcacy of the pTRP2-speciWc allo-restricted CTLs expanded from the BALB/c splenocytes by multiple stimulations with aAPCs made by coating H-2K b -Ig/pTRP2 dimeric com- plexes, anti-CD28 antibody, 4-1BBL molecules and CD83 molecules to cell-sized latex beads. The induced allo-restricted CTLs exhibited speciWc lysis against RMA-S cells pulsed with the peptide pTRP2 and H-2K b+ melanoma cells expressing TRP2, while a murine Lewis lung carcinoma cell line 3LL could not be recognized by the CTLs. The peptide-speciWc activity was inhibited by anti-H-2K b monoclonal antibody Y3. Adoptive transfer of the allo-restricted CTLs speciWc for malignant mela- noma expanded by the aAPCs can mediate eVective anti- melanoma response in vivo. These results suggested that the speciWc allo-restricted CTLs expanded by aAPCs coated with an MHC-Ig/peptide complex, anti-CD28 antibody, 4-1BBL and CD83 could be a potential option of speciWc immunotherapy for patients with malignant melanoma.
An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in Ex Vivo and in Vivo Murine Melanoma Models.

Lei Zhang,Shilong Song,Xiaoxiao Jin,Xin Wan,Khawar Ali Shahzad,Weiya Pei,Chen Zhao,Chuanlai Shen

DOI: https://doi.org/10.1158/2326-6066.cir-18-0881

IF: 10.1

2019-01-01

Cancer Immunology Research

Abstract:Antigen-presenting cells expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but are time-consuming to generate and, as live cells, raise biosafety concerns. An alternative is found in cell-free artificial antigen-presenting cells (aAPC), but these only present two or three kinds of immune molecules. Here, we describe a multipotent artificial antigen-presenting cell (MaAPC) that delivered 11 kinds of immune moleclues. This MaAPC simulated natural APCs through the concurent coupling of target antigens (H-2Kb/TRP2180-188-Ig dimers and H-2Db/gp10025-33-Ig dimers), costimulatory molecules (anti-CD28, anti-4-1BB, and anti-CD2), and "self-marker" CD47-Fc onto surface-modified polylactic-co-glycolic acid microparticles (PLGA-MP). These PLGA-MPs also encapsulated cytokines (IL2 and IL15), a chemokine (CCL21), and checkpoint inhibitors (anti-CTLA-4 and anti-PD-1). Culture of MaAPCs with naïve T cells for 1 week elevated the frequencies of TRP2180-188-specific and gp10025-33-specific CTLs to 51.0% and 43.3%, respectively, with enhanced cytotoxicity. Three infusions of MaAPCs inhibited subcutaneous melanoma growth in a mouse model and expanded TRP2180-188 and gp10025-33-specific CTLs 59-86-fold in peripheral blood, 76-77-fold in spleen, and 205-212-fold in tumor tissue, in an antigen-specific manner. Compared with conventional aAPCs carrying two or three immune molecules, the 11-signal MaAPCs exerted greater impact on T cells, including activation, proliferation, cytotoxicity, differentiation to memory CTLs or regulatory T cells and cytokines profiles, without detected side effects. Such MaAPCs could be used to individualize tumor immunotherapy.
Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes.

Shimon Slavin

DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.e14007

IF: 45.3

2019-10-07

Journal of Clinical Oncology

Abstract:e14007 Background: Immunotherapy by targeted autologous T cells, TIL or CAR-T, are considered most effective modalities for treatment of otherwise resistant cancer, yet cure is rarely achieved. In contrast, cure of resistant disease by donor lymphocyte infusion (DLI) following allogeneic stem cell transplantation suggests that alloreactive lymphocytes represent a most effective approach for elimination of resistant malignant cells. The first patient relapsing following supra-lethal chemoradiotherapy is alive & well > 34 years. Using murine B cell leukemia (BCL1) and metastatic breast cancer (4T1) we proved that non-engrafting intentionally mismatched lymphocytes activated with IL-2 that were consistently rejected cured otherwise lethal cancer with no graft-vs-host disease (GVHD). Methods: We first applied graft-vs-tumor effects by non-engrafting Intentionally Mismatched Activated Killers (IMAK) following mild immunosuppressive conditioning to maximize homeostatic proliferation of activated T & NK cells. IMAK was first applied inpatients with multiple myeloma and lymphoma treated with donor lymphocytes pre-activated in vitro prior to infusion and for 5 days following infusion withlow dose IL-2.We next studied feasibility of Allogeneic Targeted Activated Cancer Killer cells (ATACK) using IL-2 activated haploidentical donor lymphocytes including T & NK cells targeted against antigens over-expressed on the surface of malignant cells: Her-2/neu, EGFR, VEGF and CD20 using commercially available Herceptin, Erbitux, Avastin or Rituximab, respectivelyin a pilot study involving 16 patients with advanced metastatic solid tumors. Results: Using IMAK donor lymphocytes were uniformly rejected and no patient developed GVHD. Disease-free survival > 20 years was documented in our first myeloma patient with plasmacytomas and in another relapsing after autologous SCTand in 2 patients with non-Hodgkin lymphoma. Longterm progression-free survival was reported in 5 of 31 patients with resistant solid tumors. Following ATACK transient mild toxicity was manageable in outpatient clinic and no GVHD developed. Conclusions: Using ATACK against minimal residual disease accomplishable by most cancer patients following conventional 1st line treatment may result in cure of otherwise resistant cancer while avoiding GVHD.

oncology
An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.

Feng Wang,Jun Li,Dong Wang,Qian Fu,Yun-yi Xiong,Hui-ting Huang,Long-shan Liu,Chang-xi Wang

DOI: https://doi.org/10.1016/j.trim.2015.08.005

IF: 2.032

2015-01-01

Transplant Immunology

Abstract:Background: Immunological memory is one barrier to inducing immune tolerance in alloantigen primed transplant models. Alloreactive memory cells induced by primary organ transplant are difficult to suppress and contribute to rejection following a retransplant Here, we assess the effects of a novel immunosuppressive strategy on graft survival and host immune response.Materials and methods: Alloantigen primed splenocytes were adoptively transferred into naive B6 mice before heart transplant. Recipient mice were then treated with mitomycin C -pretreated donor-specific transfusion, low dose rapamycin, and anti-OX4OL mAb (alone and in combination).Results: Treatment with donor-specific transfusion + rapamycin + anti-OX4OL increased the mean graft survival time from 52 days (control group) to 42.5 days (p <0.05). None of the grafts in the control group survived past 10 days, and only 1 in 3 grafts survived at least 50 days in the combined treatment group. Compared with the control and single treatment groups, the combination of donor-specific transfusion + rapamycin + antiOX4OL inhibited infiltration of inflammatory cells; reduced the percentages of CD4+ and CD8+ memory T cells in the blood, spleen, and lymph nodes; suppressed inflammatory cytokines; reduced serum IgG levels; and enhanced the percentage of CD4 Foxp3+ T cells. The percentage of regulatory T cells was the highest in the recipients with long-term graft survivalConclusions: The combination of donor-specific transfusion + rapamycin + anti-OX4OL inhibits graft rejection mediated by memory cells and is likely to contribute to prolonged allograft survival (C) 2015 Elsevier B.V. All rights reserved.

Developments in early recall memory: normative trends and individual differences.

Antigen-specific Killer Polylactic-Co-glycolic Acid Microspheres Selectively Deplete Antigen-Specific T Cells in Vitro and in Vivo (TRAN1P.924)

Introduction to a Special Issue: Childbirth History is Everyone’s History

Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.

Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Killer artificial antigen-presenting cells treating skin allograft rejection and its impact on the overall immune function in mice model

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy

Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury.

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Antigen-specific T cell immunotherapy by in vivo mRNA delivery

In Situ Genetic Engineering of Host T-cells Based on Acellular Scaffold Strategy: a Big but Also Small Step for Solid Tumor Immunotherapy

De novo designed pMHC binders facilitate T cell induced killing of cancer cells

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy

Efficient And Selective Prevention Of Graft-Versus-Host Disease By Ag-Specific Induced Regulatory T Cells In Mice

In Vivo Anti-Melanoma Eycacy of Allo-Restricted CTLs Speciwc for Melanoma Expanded by Artiwcial Antigen-Presenting Cells

An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in Ex Vivo and in Vivo Murine Melanoma Models.

Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes.

An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.